DrugPatentWatch Database Preview
RIOMET Drug Profile
» See Plans and Pricing
Which patents cover Riomet, and what generic alternatives are available?
Riomet is a drug marketed by Ranbaxy and Sun Pharm and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighteen patent family members in eighteen countries.
The generic ingredient in RIOMET is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Seventy-nine suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Riomet
A generic version of RIOMET was approved as metformin hydrochloride by ATLAS PHARMS LLC on January 24th, 2002.
Summary for RIOMET
International Patents: | 18 |
US Patents: | 1 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 141 |
Clinical Trials: | 33 |
Patent Applications: | 38 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RIOMET |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RIOMET |
What excipients (inactive ingredients) are in RIOMET? | RIOMET excipients list |
DailyMed Link: | RIOMET at DailyMed |



Recent Clinical Trials for RIOMET
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
St. Jude Children's Research Hospital | Phase 2 |
St. Baldrick's Foundation | Phase 2 |
Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
Pharmacology for RIOMET
Drug Class | Biguanide |
Paragraph IV (Patent) Challenges for RIOMET
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
RIOMET | SOLUTION;ORAL | metformin hydrochloride | 021591 | 2018-02-02 |
US Patents and Regulatory Information for RIOMET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ranbaxy | RIOMET | metformin hydrochloride | SOLUTION;ORAL | 021591-001 | Sep 11, 2003 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Sun Pharm | RIOMET ER | metformin hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 212595-001 | Aug 29, 2019 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RIOMET
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | PA03001157 | Start Trial |
China | 1635881 | Start Trial |
Croatia | P20030161 | Start Trial |
Japan | 2004505913 | Start Trial |
Hungary | 0302700 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RIOMET
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1412357 | C 2008 016 | Romania | Start Trial | PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408 |
1261586 | 2012C/016 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE PRODUITS DE SAXAGLIPTINE ET DE METFORMINE AINSI QUE TOUT SELS PHARMACEUTIQUEMENT ACCEPTABLES, DONT LES SELS DE CHLORHYDRATE DE SAXAGLIPTINE ET DE METFORMINE; AUTHORISATION NUMBER AND DATE: EU/1/11/731/001 20111128 |
1261586 | 15/2012 | Austria | Start Trial | PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124 |
1532149 | CA 2013 00001 | Denmark | Start Trial | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720 |
1412357 | PA2008013,C1412357 | Lithuania | Start Trial | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |